Literature DB >> 33505144

Oral microbiome and pancreatic cancer.

Ai-Lin Wei1, Mao Li1, Guo-Qing Li2, Xuan Wang2, Wei-Ming Hu1, Zhen-Lu Li1, Jue Yuan1, Hong-Ying Liu1, Li-Li Zhou1, Ka Li3, Ang Li4, Mei Rosemary Fu5.   

Abstract

BACKGROUND: Microbiota profiles differ between patients with pancreatic cancer and healthy people, and understanding these differences may help in early detection of pancreatic cancer. Saliva sampling is an easy and cost-effective way to determine microbiota profiles compared to fecal and tissue sample collection. AIM: To investigate the saliva microbiome distribution in patients with pancreatic adenocarcinoma (PDAC) and the role of oral microbiota profiles in detection and risk prediction of pancreatic cancer.
METHODS: We conducted a prospective study of patients with pancreatic cancer (n = 41) and healthy individuals (n = 69). Bacterial taxa were identified by 16S ribosomal ribonucleic acid gene sequencing, and a linear discriminant analysis effect size algorithm was used to identify differences in taxa. Operational taxonomic unit values of all selected taxa were converted into a normalized Z-score, and logistic regressions were used to calculate risk prediction of pancreatic cancer.
RESULTS: Compared with the healthy control group, carriage of Streptococcus and Leptotrichina (z-score) was associated with a higher risk of PDAC [odds ratio (OR) = 5.344, 95% confidence interval (CI): 1.282-22.282, P = 0.021 and OR = 6.886, 95%CI: 1.423-33.337, P = 0.016, respectively]. Veillonella and Neisseria (z-score) were considered a protective microbe that decreased the risk of PDAC (OR = 0.187, 95%CI: 0.055-0.631, P = 0.007 and OR = 0.309, 95%CI: 0.100-0.952, P = 0.041, respectively). Among the patients with PDAC, patients reporting bloating have a higher abundance of Porphyromonas (P = 0.039), Fusobacterium (P = 0.024), and Alloprevotella (P = 0.041); while patients reporting jaundice had a higher amount of Prevotella (P = 0.008); patients reporting dark brown urine had a higher amount of Veillonella (P = 0.035). Patients reporting diarrhea had a lower amount of Neisseria and Campylobacter (P = 0.024 and P = 0.034), and patients reporting vomiting had decreased Alloprevotella (P = 0.036).
CONCLUSION: Saliva microbiome was able to distinguish patients with pancreatic cancer and healthy individuals. Leptotrichia may be specific for patients living in Sichuan Province, southwest China. Symptomatic patients had different bacteria profiles than asymptomatic patients. Combined symptom and microbiome evaluation may help in the early detection of pancreatic cancer. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  16s rRNA; Cancer detection; Dysbiosis; High-throughput sequencing; Oral microbiota; Pancreatic cancer

Mesh:

Substances:

Year:  2020        PMID: 33505144      PMCID: PMC7789059          DOI: 10.3748/wjg.v26.i48.7679

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


Core Tip: Pancreatic adenocarcinoma (PDAC) patients benefit from early detection. This study analyzed the composition and diversity of saliva microbiota in PDAC patients through 16S ribosomal ribonucleic acid sequencing. Normalized z-score of bacteria abundance associated clinical data were analyzed for PDAC risk prediction. Microbiome abundance differences were found between PDAC patients with symptoms and patients without symptoms. Combined symptom and microbiome evaluation may help in early detection and risk prediction of pancreatic cancer.

INTRODUCTION

Pancreatic cancer or pancreatic adenocarcinoma (PDAC) is a lethal disease with a 5-year survival rate of about 6%[1,2]. Early detection and diagnosis are essential for effective surgery treatment that improves cancer survival[3,4], yet these remain a great challenge. A variety of diagnostic methods are available. For example, deoxyrib-onucleic acid (DNA) sequencing for detecting and diagnosing pancreatic cancer are limited in clinical use due to the need for fresh, high-quality specimens, tumor content, and tumor heterogeneity[5,6]. Molecular markers, such as mutant DNA or DNA methylomes, are also limited in clinical use to enhance diagnostic sensitivity or early detection of pancreatic cancer recurrence[7,8]. Biomarker Ca19-9 has been commonly used for diagnosis and prognosis of pancreatic cancer with diagnostic sensitivity of 0.78 and specificity of 0.77, but this biomarker test has limited sensitivity among patients with jaundice, pancreatitis, enteritis, and elevated blood glucose, since such patients usually have elevated Ca19-9 concentrations[9-11]. In addition, 7%-10% Lewis (a-/b-) populations could not express Ca19-9[12]. The oral or fecal microbiota profile of gastrointestinal and colorectal cancer, oropharyngeal cancer, liver cancer, and lung cancer may be a novel and potential diagnostic biomarker[13-19]. Accumulated studies have revealed that oral and gastrointestinal microbiomes differ in abundance in patients with pancreatic cancer compared with healthy individuals[20-23]. Cancer risk increases with carriage of Porphyromonas gingivalis[21], Actinobacillus actinomycetemcomitans[21], and Alloprevotella[21], while Fusobacterium[21,24], Leptotrichia[21,25,26], Neisseria elongate[21,23], and Streptococcus mitis[21,23] might be a protective factor for having pancreatic cancer. However, Olson et al[22] did not find significant differences in the diversity of the oral microbiome among PDAC patients (n = 40), intraductal papillary mucinous neoplasms (IPMNs) (n = 39), and healthy participants (n = 58) in the United States[22]. The conflicting findings in the prior studies may be due to the differences in methodological approach and sample collection. For example, some studies performed real-time quantitative polymerase chain reaction (PCR) for validation of bacterial candidates[23], and some sequenced the microbiota profile in samples of tongue coating[20] or oral wash samples[21]. Tongue coating change is a major often-used approach of tongue diagnosis in traditional Chinese medicine, but tongue coating can only capture partial oral microbiota[27,28]. The oral wash method is more complicated and relatively expensive. Oral cavity contains nearly 619 taxa in 13 phyla (Firmicutes, Proteobacteria, Actinobacteria, Fusobacteria, Bacteroidetes, Chlamydiae, Chloroflexi, Euryarchaeota, Spirochaetes, SR1, Synergistes, Tenericutes, and TM7), and 68% of these bacteria are uncultivated phylotypes[29,30]. Advanced genomic sequencing for human oral microbiome distribution makes it possible to measure the proportions of bacterial species without relying on traditional culture methods[31-33]. Saliva has been found to contain broad spectrum of bacteria with easy sampling method and is relatively cost-effective. Although there are some studies on oral flora and pancreatic cancer in non-Chinese population, the impact of geographical and medical factors, such as race and ethnicity, different dietary habits, antibiotic use, and cancer, may make the oral microbial profile differ among people from different geographic locations. In addition, there are few studies on oral saliva flora and pancreatic cancer in China. Thus, the purpose of our study was to: (1) Determine the saliva microbiome distribution of pancreatic cancer (including resectable PDAC and unresectable PDAC) among Chinese population using 16S rRNA sequencing; and (2) Select proper and specific microbiota for PDAC detecting.

MATERIALS AND METHODS

Ethical consideration

The Institutional Review Board of the West China Hospital, Sichuan University approved this prospective study. All participants signed written informed consent.

Research design and participants

This was a prospective study. We consecutively recruited 80 patients who were over age 18 years and suspected to have pancreatic tumor prior to biopsy or surgery. Histopathological results confirmed 45 patients with primary PDAC and 35 patients with non-cancer pancreatic tumors, including 9 IPMN, 11 pancreatic serous cystadenoma, 5 solid pseudopapillary neoplasm, and 10 neuroendocrine tumors. We also recruited 69 healthy participants from the community as a comparison group. Healthy adults had normal liver and renal function, normal cardio-pulmonary function, no history of cancer, and no viral infection. Participants were excluded if they had: (1) A history of prior malignancy and chemotherapy or radiotherapy; (2) Metastatic PDAC or PDAC with other cancer; (3) A history of viral infection (i.e. hepatitis B virus, hepatitis C virus, human immunodeficiency virus); (4) Use of antibiotics (including oral, intravenous, or intramuscular) and probiotics within 4 wk prior to enrollment; and (5) Use of corticosteroids (nasal or inhaled) or other immunosuppressants. In addition, we excluded participants with insufficient saliva sample (n = 12) for sequencing analysis and patients with non-cancer pancreatic tumors (n = 35).

Demographic and clinical phenotype

The demographic information collected included age, gender, body mass index (BMI), smoking history, alcohol consumption, dietary habit, and chronic diseases (hypertension and type II diabetes). Clinical information was also collected to include cancer site, surgery type, and cancer stages using the American Joint Commission on Cancer, seventh edition staging manual[34].

Symptom phenotype

Since there is no measure or checklist for symptoms specific to pancreatic cancer, we developed a checklist based on literature review to assess symptoms specific to pancreatic cancer, such as bloating, jaundice, nausea, vomiting, dark brown urine, diarrhea, constipation, pale stools, pruritus, lack of appetite, pain, fatigue, and disturbed sleeping. Patients reported the presence and absence of symptoms by checking “Yes” or “No.”

Saliva sample collection

Before the patients had surgery to confirm pancreatic cancer diagnosis, saliva samples were collected by trained professionals (Wang X and Li GQ). All the participants were instructed to not eat and drink for 0.5 h prior to saliva sample collection. Participants were also instructed not to brush their teeth at least 8 h prior to saliva sample collection, since brushing teeth may remove part of the oral flora. Participants were asked to rinse their mouths to remove debris from the oral cavity before saliva collection. To ensure all sample collection was at a similar time period in a day, we collected patient samples around 4:00 pm on the day of admission prior to biopsy or surgery for cancer diagnosis. Healthy subjects’ saliva samples were also collected around 4:00 pm in the afternoon. About 3 mL saliva was collected in a sterile tube after it accumulated on the mouth floor. The fresh samples were placed on ice and transported to the laboratory. Samples were divided into 1.5 mL aliquots and stored immediately at -80 °C.

Genome DNA extraction

We used the PowerSoil DNA Isolation Kit (MO BIO Laboratories, Carlsbad, CA, United States) to extract bacterial genomic DNA from saliva samples. DNA concentration and purity was quantified by Qubit 3.0 Fluorometer (Thermo Fisher Scientific, Wilmington, DE, United States) and agarose gel electrophoresis. Genome DNA with strong smear or with concentration lower than 5 μg/mL (by Qubit) was excluded for library construction.

16S rRNA gene sequencing

The third and fourth hypervariable regions (V3-V4) of the 16S rRNA gene of bacteria were amplified by PCR with a domain-specific primer: 341F (5'-CCTACGGGNGGCWGCAG-3') and 805R (5'- GACTACHVGGGTATCTA ATCC-3'). PCR reactions were performed with a 15 µL of Phusion® High-Fidelity PCR Master Mix (New England Biolabs, Ipswich, MA, United States), 0.2 μmol/L of forward and reverse primers, and about 10 ng template DNA. Thermal cycling consisted of initial denaturation at 98 °C for 1 min, followed by 30 cycles of denaturation at 98 °C for 10 s, annealing at 50 °C for 30 s, and elongation at 72 °C for 30 s. Finally, samples were incubated at 72 °C for 5 min. The library quality was assessed by Agilent Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA, United States). Sequencing was performed on an Illumina Novaseq6000 sequencing platform (Illumina, San Diego, CA, United States), and 250 bp paired-end reads were generated.

Statistical analysis

Phenotype data analysis: Statistical analyses were performed using SPSS (v23.0, SAGE IBM, Armonk, NY, United States). Continuous variables (age and BMI) were estimated as average ± standard error, and categorical variables were analyzed in terms of frequencies and percentages. Chi square analysis and Fisher’s exact tests were used for categorical variables; t-test and Mann-Whitney U test were used for continuous variables. All tests were two-sided, and P values < 0.05 were considered statistically significant with 95% confidence interval (CI).

Microbiome data analysis

Profile and quality assurance: Raw sequences were denoised via FLASH (V1.2.7, http://ccb.jhu.edu/software/FLASH/)[35]. Quality filtering was performed on raw sequences using QIIME quality control process (v1.9.1_http://qiime.org/index.html) and then high quality clean tags were obtained[36]. Tags were compared with gold database (http://drive5.com/uchime/uchime_download.html), and chimeras were removed with the UCHIME algorithm (v11.0, http://www.drive5.com/usearch/manual/uchime_algo.html)[37]. Effective Tags were finally obtained. All effective sequence analysis was performed by Uparse software (v7.0.1001, http://drive5.com/uparse/)[38]. The optimized, high-quality sequences were clustered into operational taxonomic units (OTUs) at 97% sequence identity. Microbiome diversity: According to the results of OTUs clustering analysis and the research requirements, the Venn diagram was constructed to illustrate the number of unique and shared species in saliva samples between PDAC and healthy groups. The Venn diagram was made using R program (Package_VennDiagram). We applied alpha diversity to analyze complexity of species diversity for a sample. Four indices were used: “Chao1” and “Abundance-based coverage estimator (ACE)” estimate the species abundance; “Shannon index ” and “Simpson” account for the richness and evenness. The value of Simpson index was calculated as Simpson’s index of diversity 1-D. Thus, higher Shannon and Simpson indices mean higher species diversity. All indices were calculated with QIIME (v1.9.1) and R software (V2.15.3, Auckland, New Zealand). We compared four indices between PDAC and healthy control group using Mann-Whitney U test. Mann-Whitney U test was used to compare the alpha diversity indices between groups of resectable PDAC (rPDAC) and unresectable PDAC (unrPDAC). The bacterial taxonomic compositions were evaluated with a linear discriminant analysis effect size algorithm (https://huttenhower.sph.harvard.edu/). P < 0.05 and an LDA score ≥ 2.0 were recognized as significant in Kruskal–Wallis and pairwise Wilcoxon evaluation, respectively. Abundance of bacteria and symptom: We used Wilcoxon rank-sum test to compare the abundance of bacteria (top 10 positively expressed flora) in PDAC patients with and without typical symptoms of PDAC, including bloating, jaundice, nausea, vomiting, dark brown urine, diarrhea, constipation, pale stools, pruritus, lack of appetite, pain, fatigue, and disturbed sleeping.

Risk prediction for PDAC

Logistic regressions were used to explore the association of significant taxa with clinical covariates (age, BMI, smoking status, alcohol consumption status, history of blood hypertension, and eating habits). To avoid the occurrence of false negative diagnosis, we focused on the top 20 species (OTUs abundance) and the flora associated with PDAC that has been reported[20-23]. Finally, Streptococcus, Prevotella, Porphyromonas, Neisseria, Veillonella, Leptotrichia, Lactobacillus, Actinomyces, Haemophilus, Rothia, and Fusobacterium were selected for analysis. To make the values comparable, we converted the OTU values of all selected taxa into a normalized z-score. The tetranucleotide-derived z-score, superior to (G + C) content differences, was calculated according to the previous methods[39,40]. Odds ratio with 95%CIs were calculated.

RESULTS

Phenotypic characteristics

Between November 2017 and December 2018, a total of 157 participants were enrolled in this study; four PDAC patients and eight healthy participants were eventually excluded due to the insufficient saliva sample for sequencing analysis. A final sample of 110 included patients in PDAC (n = 41) and healthy individuals (n = 69). Table 1 shows the demographic characteristics of PDAC patients and healthy participants. Compared with the healthy group, the PDAC had lower BMIs (22.76 vs 24.44, P < 0.0001). As for eating habits, more PDAC patients (61%) preferred oily and fatty foods compared to the healthy control group (P = 0.002). More healthy control participants had hypertension (P = 0.006). Among the 41 patients with PDAC, 31 (76%) had head pancreatic cancer, and 20 (49%) patients had resectable pancreatic cancer.
Table 1

Demographic characteristics of participants

Variables
PDAC group, n = 41
Healthy control group, n = 69
P value
Age, average ± standard error61.17 ± 1.7964.64 ± 1.040.098
Gender, n (%)
Male24 (59)50 (72)0.132
Female17 (41)19 (28)
BMI, average ± standard error22.76 ± 0.9424.44 ± 0.39< 0.0001
Smoking history, n (%)17 (41)37 (54)0.217
Alcohol consumption, n (%)16 (39)30 (43)0.647
Dietary habit, n (%)
Oily and fatty food25 (61)21 (31)0.002
Salty food6 (15)8 (11)0.664
Light diet10 (24)40 (58)0.001
Chronic disease, n (%)
Hypertension1 (2)15 (22)0.006
Type II diabetes2 (5)6 (9)0.714
Both3 (7)5 (7)1.000
Loss of weight, n (%)23 (56)3 (4)0.0001
Primary cancer site, n (%)
Head31 (76)NANA
Body and tail10
Surgery, n (%)
Pancreaticoduodenectomy14 (34)NANA
Distal pancreatectomy6 (15)
Palliative intervention techniques21 (51)
AJCC stagingNANA
I-IIB20 (49)
III-IV21

AJCC: American Joint Commission on Cancer; BMI: Body mass index; PDAC: Pancreatic adenocarcinoma.

Demographic characteristics of participants AJCC: American Joint Commission on Cancer; BMI: Body mass index; PDAC: Pancreatic adenocarcinoma.

Bacteria profile

Alpha-diversity analysis of the study participant groups: From 110 samples, we filtered 6356399 qualified reads. We randomly chose 2235200 reads (110 samples multiplied by 20320 reads/sample, the minimum number of reads/sample). Finally, we obtained 1975 OTUs for further analysis. A Venn diagram (Figure 1) shows the details of the OTUs at 97% identity for PDAC patients and healthy participants. The two groups had 690 shared species, 231 unique species for PDAC patient, and 389 for healthy control group. As Table 2 shows, compared with the healthy group, the PDAC group had significantly increased microbial abundance estimated by the Chao1 index and ACE index while decreased microbial diversity estimated by Shannon and Simpson indices (P < 0.0001). Patients with rPDAC had lower bacteria abundance and diversity than patients with unrPDAC estimated by Chao1, ACE, Shannon indices, and Simpson indices. However, Shannon (P = 0.273), Simpson (P = 0.715), Chao1 (P = 0.159), and ACE (P = 0.137) were not able to distinguish rPDAC and unrPDAC.
Figure 1

Microbial profiles of two groups. Venn diagram showing shared and unique operational taxonomic units (OTUs) at 97% identity among pancreatic adenocarcinoma (PDAC) group (n = 41) and healthy controls (HC) group (n = 69). PDAC group is blue; HC group is green. OTUs (690) are shared by two groups. Unique OTUs of 231 and 389 were found in PDAC and HC, respectively.

Table 2

α-diversity indices of two groups


PDAC group, n = 41
Healthy control group, n = 69
P value
Shannon5.14 ± 0.675.67 ± 0.510.0001
Simpson0.90 ± 0.080.95 ± 0.020.0001
Chao1423.48 ± 55.69295.00 ± 54.050.0001
ACE424.00 ± 55.72293.97 ± 50.090.0001

PDAC: Pancreatic adenocarcinoma.

Microbial profiles of two groups. Venn diagram showing shared and unique operational taxonomic units (OTUs) at 97% identity among pancreatic adenocarcinoma (PDAC) group (n = 41) and healthy controls (HC) group (n = 69). PDAC group is blue; HC group is green. OTUs (690) are shared by two groups. Unique OTUs of 231 and 389 were found in PDAC and HC, respectively. α-diversity indices of two groups PDAC: Pancreatic adenocarcinoma.

Bacterial taxonomic alterations in PDAC

We used a linear discriminant analysis effect size algorithm to assess the bacterial taxonomic compositions and differences between PDAC group and healthy control subjects. Compared with the healthy group, PDAC patients were significantly enriched in order_Lactobacillales, class_Bacilli, genus_Streptococcus, phylum_Firmicutes, genus_Actinomyces, genus_Rothia, genus_Leptotrichia, genus_Lactobacillus, species_Escherichia_coli, and order_Enterobacteriales (Figure 2A). Conversely, PDAC patients had significantly reduced abundances of Selenomonas, Porphyromnas, Prevotella, Capnocytophaga, Alloprevotella, Tannerella, and Neisseria at genus level. We also compared the bacterial distributions between rPDAC and unrPDAC patients. Figure 2B shows that species_Escherichia coli, genus_Peptostreptococcus, genus_Asteroleplasma, and species_Tannerella forstythia were more prevalent in the unrPDAC group, whereas we found reduced occurrence of species_Bacteroides stercoris, genus_Megasphaera, and genus_Veillonella (Figure 2).
Figure 2

Linear discriminant analysis effect size and latent dirichlet allocation analysis based on operational taxonomic units. A: Shows a list of specific oral bacteria that enable discrimination between pancreatic adenocarcinoma (PDAC) patients and healthy controls (HC). Differences in oral microbial communities between PDAC patients and HC. The horizontal line with red and green denotes the means of the HC and PDAC groups, respectively; B: Resectable PDAC (rPDAC) and unresectable PDAC (unrPDAC). Differences in oral microbial communities between rPDAC group and unrPDAC. The horizontal line with red and green denotes the means of the rPDAC and unrPDAC groups, respectively.

Linear discriminant analysis effect size and latent dirichlet allocation analysis based on operational taxonomic units. A: Shows a list of specific oral bacteria that enable discrimination between pancreatic adenocarcinoma (PDAC) patients and healthy controls (HC). Differences in oral microbial communities between PDAC patients and HC. The horizontal line with red and green denotes the means of the HC and PDAC groups, respectively; B: Resectable PDAC (rPDAC) and unresectable PDAC (unrPDAC). Differences in oral microbial communities between rPDAC group and unrPDAC. The horizontal line with red and green denotes the means of the rPDAC and unrPDAC groups, respectively.

Microbiome profile and symptoms

Table 3 presented flora abundance differences between the PDAC patients with symptoms and without symptoms. Patient reporting bloating had greater abundance of Porphyromonas (660.4 ± 461.0, P = 0.039), Fusobacteria (490.0 ± 186.6, P = 0.024), and Alloprevotella (155.4 ± 124.1, P = 0.041) compared to those without bloating (412.0 ± 394.3, 361.8 ± 184.4 and 99.3 ± 81.9, respectively). Prevotella presented greater abundance in patients without jaundice (669.4 ± 384.3, P = 0.008) compared to those with jaundice (403.2 ± 310.8). Veillonella presented greater abundance in patients without dark brown urine (1863.8 ± 1449.2, P = 0.035) compared to those with dark brown urine (1018.6 ± 766.7). Alloprevotella presented greater abundance in patients without vomiting (130.3 ± 100.9, P = 0.036) compared to those with vomiting (91.8 ± 134.4), while Neisseria presented greater abundance in patients with vomiting (3343.3 ± 1829.9, P = 0.024) compared to those without vomiting (1360.3 ± 1256.6). Campylobacter presented greater abundance in patients with diarrhea (130.5 ± 59.7, P = 0.034) compared to those without diarrhea (74.9 ± 87.2).
Table 3

Flora abundance differences in pancreatic adenocarcinoma patients with symptomatic phenotype

Symptoms
Microbiome
Without symptoms
With symptoms
P value
Bloating Porphyromonas 412.0 ± 394.3660.4 ± 461.00.039
Fusobacteria 361.8 ± 184.4490.0 ± 186.60.024
Alloprevotella 99.3 ± 81.9155.4 ± 124.10.041
Jaundice Prevotella 669.4 ± 384.3403.2 ± 310.80.008
Dark brown urine Veillonella 1863.8 ± 1449.21018.6 ± 766.70.035
Vomiting Alloprevotella 130.3 ± 100.991.8 ± 134.40.036
Diarrhea Neisseria 1360.3 ± 1256.63343.3± 1829.90.024
Campylobacter 74.9 ± 87.2130.5 ± 59.70.034
Flora abundance differences in pancreatic adenocarcinoma patients with symptomatic phenotype

Logistic regression for microbiota profile

We explored the PDAC risk in relation to selected bacteria abundances (normalized z-score). As shown in Table 4, compared with healthy control group, carriage of Streptococcus (OR = 5.344, 95%CI: 1.282-22.282, P = 0.021) and Leptotrichina (OR = 6.886, 95%CI: 1.423-33.337, P = 0.016) were associated with a higher risk of PDAC. With each increase of z-score of Streptococcus and Leptotrichina in PDAC patients, the risk of pancreatic cancer increased by 5.344 odds and 6.886 odds, respectively. Carriage of Veillonella and Neisseria were protective factors of having PDAC (OR = 0.187, 95%CI: 0.055-0.631, P = 0.007 and OR = 0.309, 95%CI: 0.100-0.952, P = 0.041, respectively). With each decrease of z-score of Veillonella and Neisseria in PDAC patients, the risk of pancreatic cancer decreased by 0.187 odds and 0.309 odds, respectively.
Table 4

Oral bacteria distribution and risk of pancreatic adenocarcinoma


Odds ratio
95%CI
P value
Healthy control groupBase outcome
PDAC group
Age0.9560.8751.0460.327
BMI0.9730.7081.3380.866
Oily and fatty food0.7590.1224.7300.768
Streptococcus 5.3441.28222.2820.021
Veillonella 0.1870.0550.6310.007
Neisseria 0.3090.1000.9520.041
Lactobacillus 0.7130.3571.4250.338
Leptotrichia 6.8861.42333.3370.016
Actinomyces 4.5150.44445.8870.203
Haemophilus 1.1850.5132.7380.691
Prevotella 0.6730.2981.5190.341
Porphyromonas 0.2940.0841.0330.056
Rothia 1.2570.4673.3840.650
Fusobacterium 1.0060.3353.0170.576

BMI: Body mass index; CI: Confidence interval; PDAC: Pancreatic adenocarcinoma.

Oral bacteria distribution and risk of pancreatic adenocarcinoma BMI: Body mass index; CI: Confidence interval; PDAC: Pancreatic adenocarcinoma.

DISCUSSION

This prospective study found dysbacteriosis of the oral microbiota existed in patients with PDAC. Fecal bacteria flora has been the main sample method for research on pancreatic cancer[41,42]. Our study used saliva sample method, which is convenient and the quality of sample is easy to control during sample collection. When comparing bacteria profiles from our saliva samples and fecal samples from other research on Chinese PDAC patients[20,42], salivary and intestinal bacteria flora consistently had low Shannon index and high Chao1 index, and Lactobacillus, Enterobacter, and Leptotrichia at the genus level was significantly increased. This provides supporting evidence that saliva sample method yields similar bacteria flora profiles compared to the fecal sample method, which is very often difficult to collect the samples. Findings of our study also provided additional evidence to confirm that Neisseria and Streptococcaceae are risk factors for pancreatic cancer[21,23]. Currently, no studies have focused on comparing the advantages and disadvantages of using different sample collection techniques, and studies are necessary to compare the effectiveness of using different sample collection techniques, such as saliva, tongue coating, and oral wash, on sample quality for microbiota profiles and preference of patients. In terms of microbiota abundance and species diversity, our study found that the PDAC group had significantly increased microbial abundance as estimated by the Chao1 and ACE indices and decreased microbial diversity as estimated by Shannon and Simpson indices. Lu et al[20] also had similar findings from a study on Chinese pancreatic cancer patients using tongue coating samples[20]. However, studies of non-Chinese population did not find any differences of alpha diversity indices of oral microbiota composition between pancreatic cancer patients and healthy individuals[22,23]. Findings of our study and Lu et al[20] demonstrated that seven of fourteen bacterial families (Leptotrichiaceae, Actinomycetaceae, Lachnospiraceae, Micrococcaceae, Erysipelotrichaceae, Coriobacteriaceae, Moraxellaceae) were consistently significantly increased, and Porphyromonadaceae was significantly decreased in Chinese PDAC patients. However, our study found that the abundance of three of fourteen bacterial families (Fusobacteriaceae, Campylobacteraceae, Spirochaetaceae) were significantly decreased in PDAC patients, while Lu et al[20] found significantly more abundance[20]. Both our study and the study by Lu et al[20] found significant increase in the genus of Leptotrichia, Actinomyces, Rothia, Rothia, Solobacterium, Peptostreptococcus, and Oribacterium. Yet, decreased abundance in Selenomona, Tannerella, and Campylobacter was found in our study using saliva sample method but was increased in the study by Lu et al[20] using tongue coating sample method[20]. There are four known main periodontal disease contributors: Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, and Prevotella intermedia were more prevalent in PDAC patients in Fan et al[21]. However, except for Actinomyces, Porphyromonas gingivalis, Tannerella forsythia, and Prevotella intermedia were significantly reduced in our study. Leptotrichia also showed different distribution in our study comparing to Fan et al[21]. Torres et al[43] found higher Leptotrichia and lower Porphyromonas in the saliva of patients with pancreatic cancer, but no significant differences were found in the expression of Streptococcus mitis and Granulicatella adiacens. The conflicting findings between our study and other studies may due to different sample collection methods, e.g., saliva vs tongue coating method. Future research should compare different sample collection methods for microbiome research, e.g., saliva vs tongue coating method. The other factor for the conflicting findings may geographic food preferences of Chinese population. For example, subjects in Lu et al[20]’s study were enrolled from Zhejiang University, which is located in Hangzhou (southeast of China). Generally, people in Hangzhou have different diet preferences, such as preferences for milder taste and more sugar. Subjects in our study from Sichuan Province preferred adding a large amount of different herbs and spices and more fat and salt in food, which may lead to a high incidence of digestive system tumors[44,45]. Future research should focus on the effects of geographical location, race, diet, antibiotic usage (including consuming meat products containing antibiotics), injury, illness, and hormonal change on flora analysis[46]. One important finding of our study was that bacteria flora was able to differentiate patients with rPDAC and unrPDAC. This is important because patients with rPDAC usually have better prognosis with timely surgical treatment. We found that species_Escherichia coli and species_Tannerella forstythia were increased significantly in unrPDAC, and these bacteria may be able to predict a tumor that is already advanced. In contrast, the expression of Veillonella demonstrated a gradual decline in saliva samples from healthy people, rPDAC, and advanced PDAC (Figure 3), which indicates that Veillonella may be protective bacteria for PDAC development.
Figure 3

The abundance of The relative abundance of Veillonella in pancreatic adenocarcinoma (PDAC) patients is shown by the straight, and dotted lines plot the means and medians of the relative abundance. The abundance of Veillonella showed a gradual decline in saliva samples from healthy people, resectable PDAC (rPDAC), and unresectable PDAC (unrPDAC). HC: Healthy controls.

The abundance of The relative abundance of Veillonella in pancreatic adenocarcinoma (PDAC) patients is shown by the straight, and dotted lines plot the means and medians of the relative abundance. The abundance of Veillonella showed a gradual decline in saliva samples from healthy people, resectable PDAC (rPDAC), and unresectable PDAC (unrPDAC). HC: Healthy controls. Our study is the first to investigate the associations between bacteria profiles and symptoms related to pancreatic cancer. Symptomatic patients had different bacteria profiles than asymptomatic patients in our study. For examples, PDAC with bloating have a higher abundance of Porphyromonas, Fusobacterium, and Alloprevotella, and Alloprevotella is decreased in patients with vomiting. In addition, PDAC with jaundice had a higher amount of Prevotella compared with the PDAC without jaundice. There was a higher amount of Veillonella in patients with dark brown urine. PDAC with diarrhea had a lower amount of Neisseria and Campylobacter compared with PDAC without diarrhea. One benefit of having symptoms is that patients will seek medical help earlier, leading to the diagnosis of early PDAC and improved survival. The exact microbiome mechanism for symptoms is unknown, and more studies are needed to investigate the associations between microbiota and symptoms. Perhaps, combined symptom and microbiome evaluation may help in early detection of pancreatic cancer. Our study had limitations. We did not include the data of other pancreatic diseases because the sample size was very small. Second, we used only 16S rRNA sequencing to analyze bacterial distributions; future research should include metagenomic sequencing to enhance accuracy of bacterial distributions. It should be noted that the rapid, inexpensive tests of 16S rRNA sequencing can have advantages for clinical implementation by using bacterial distribution test for early detection or prevention of PDAC. Some studies found the association between microbiome profile and dental disease[47]. Another limitation of our study was that we were not able to exclude participants with dental disease since our participants were not able to provide accurate history of dental disease, and there were no medical record regarding dental disease for us to verify participant dental disease status. In the future, it may be beneficial to have a professional dentist examine participant’s oral health status so as to ascertain the potential impact of oral health status on microbiome flora profile among patients with pancreatic cancer. One strength of the study is that we compared the bacteria abundances in patients with positive symptoms to find the relative association between the occurrence of symptoms and potential functions of flora.

CONCLUSION

Saliva microbiome are able to distinguish PDAC and healthy individuals. Higher Streptococcus and Leptotrichia abundances were associated with increased risk of PDAC. Veillonella and Neisseria were protective factors for detecting PDAC. Neisseria was recognized by all studies to reduce the risk of pancreatic cancer while Leptotrichia was identified in our study as a potential specific detector of PDAC in patients living in Sichuan Province, southwest China. Symptomatic patients had different bacteria profiles than asymptomatic patients. As symptoms of PDAC are usually nonspecific, combined symptom and microbiome evaluation may help in early detection of pancreatic cancer. Understanding the distribution of bacteria flora is essential step for developing probiotic treatment plans for reducing the risk of pancreatic cancer.

ARTICLE HIGHLIGHTS

Research background

Understanding the distribution of bacteria flora is essential step for developing probiotic treatment plans for reducing the risk of pancreatic cancer.

Research motivation

The impact of geographical and medical factors, such as race and ethnicity, different dietary habits, antibiotic use, and cancer, may make the oral microbial profile differ among people from different geographic locations.

Research objectives

To investigate the saliva microbiome distribution in patients with pancreatic adenocarcinoma and the role of oral microbiota profiles in detection and risk prediction of pancreatic cancer.

Research methods

A prospective design was utilized with 16S ribosomal ribonucleic acid gene sequencing to identify differences in bacterial taxa using a linear discriminant analysis effect size algorithm. Operational taxonomic unit values of all selected taxa were converted into a normalized Z-score, and logistic regressions were used to calculate risk prediction of pancreatic cancer.

Research results

Saliva microbiome was able to distinguish patients with pancreatic cancer and healthy individuals. Symptomatic patients had different bacteria profiles than asymptomatic patients.

Research conclusions

Combined symptom and microbiome evaluation may help in early detection of pancreatic cancer.

Research perspectives

Further work may focus on specific microbiota verification and diagnostic ability via large sample studies.
  47 in total

1.  Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform.

Authors:  James J Kozich; Sarah L Westcott; Nielson T Baxter; Sarah K Highlander; Patrick D Schloss
Journal:  Appl Environ Microbiol       Date:  2013-06-21       Impact factor: 4.792

2.  Oral Health and the Oral Microbiome in Pancreatic Cancer: An Overview of Epidemiological Studies.

Authors:  Paige M Bracci
Journal:  Cancer J       Date:  2017 Nov/Dec       Impact factor: 3.360

Review 3.  Risk factors for pancreatic cancer: a summary review of meta-analytical studies.

Authors:  Patrick Maisonneuve; Albert B Lowenfels
Journal:  Int J Epidemiol       Date:  2014-12-14       Impact factor: 7.196

4.  Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study.

Authors:  Dominic G Rothwell; Mahmood Ayub; Natalie Cook; Fiona Thistlethwaite; Louise Carter; Emma Dean; Nigel Smith; Shaun Villa; Joanne Dransfield; Alexandra Clipson; Daniel White; Kamrun Nessa; Saba Ferdous; Matthew Howell; Avinash Gupta; Bedirhan Kilerci; Sumitra Mohan; Kris Frese; Sakshi Gulati; Crispin Miller; Allan Jordan; Helen Eaton; Nicholas Hickson; Ciara O'Brien; Donna Graham; Claire Kelly; Sreeja Aruketty; Robert Metcalf; Jaseela Chiramel; Nadina Tinsley; Alexander J Vickers; Roopa Kurup; Hannah Frost; Julie Stevenson; Siobhan Southam; Dónal Landers; Andrew Wallace; Richard Marais; Andrew M Hughes; Ged Brady; Caroline Dive; Matthew G Krebs
Journal:  Nat Med       Date:  2019-04-22       Impact factor: 53.440

5.  Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer.

Authors:  James J Farrell; Lei Zhang; Hui Zhou; David Chia; David Elashoff; David Akin; Bruce J Paster; Kaumudi Joshipura; David T W Wong
Journal:  Gut       Date:  2011-10-12       Impact factor: 23.059

6.  The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study.

Authors:  Sara H Olson; Jaya Satagopan; Youming Xu; Lilan Ling; Siok Leong; Irene Orlow; Amethyst Saldia; Peter Li; Pamela Nunes; Vincent Madonia; Peter J Allen; Eileen O'Reilly; Eric Pamer; Robert C Kurtz
Journal:  Cancer Causes Control       Date:  2017-07-31       Impact factor: 2.506

7.  QIIME allows analysis of high-throughput community sequencing data.

Authors:  J Gregory Caporaso; Justin Kuczynski; Jesse Stombaugh; Kyle Bittinger; Frederic D Bushman; Elizabeth K Costello; Noah Fierer; Antonio Gonzalez Peña; Julia K Goodrich; Jeffrey I Gordon; Gavin A Huttley; Scott T Kelley; Dan Knights; Jeremy E Koenig; Ruth E Ley; Catherine A Lozupone; Daniel McDonald; Brian D Muegge; Meg Pirrung; Jens Reeder; Joel R Sevinsky; Peter J Turnbaugh; William A Walters; Jeremy Widmann; Tanya Yatsunenko; Jesse Zaneveld; Rob Knight
Journal:  Nat Methods       Date:  2010-04-11       Impact factor: 28.547

Review 8.  Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review.

Authors:  R D Neal; P Tharmanathan; B France; N U Din; S Cotton; J Fallon-Ferguson; W Hamilton; A Hendry; M Hendry; R Lewis; U Macleod; E D Mitchell; M Pickett; T Rai; K Shaw; N Stuart; M L Tørring; C Wilkinson; B Williams; N Williams; J Emery
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

9.  Altered oral microbiota in chronic hepatitis B patients with different tongue coatings.

Authors:  Yu Zhao; Yu-Feng Mao; Yi-Shuang Tang; Ming-Zhu Ni; Qiao-Hong Liu; Yan Wang; Qin Feng; Jing-Hua Peng; Yi-Yang Hu
Journal:  World J Gastroenterol       Date:  2018-08-14       Impact factor: 5.742

Review 10.  Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.

Authors:  Prashanth Rawla; Tagore Sunkara; Vinaya Gaduputi
Journal:  World J Oncol       Date:  2019-02-26
View more
  14 in total

Review 1.  Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications.

Authors:  Suneetha Amara; Li V Yang; Venkataswarup Tiriveedhi; Mahvish Muzaffar
Journal:  Cells       Date:  2022-06-11       Impact factor: 7.666

Review 2.  The oral microbiome, pancreatic cancer and human diversity in the age of precision medicine.

Authors:  Kelly M Herremans; Andrea N Riner; Miles E Cameron; Kelley L McKinley; Eric W Triplett; Steven J Hughes; Jose G Trevino
Journal:  Microbiome       Date:  2022-06-15       Impact factor: 16.837

Review 3.  The Microbiome in Pancreatic Cancer-Implications for Diagnosis and Precision Bacteriophage Therapy for This Low Survival Disease.

Authors:  Mwila Kabwe; Stuart Dashper; Joseph Tucci
Journal:  Front Cell Infect Microbiol       Date:  2022-05-19       Impact factor: 6.073

4.  Microbial Characteristics of Common Tongue Coatings in Patients with Precancerous Lesions of the Upper Gastrointestinal Tract.

Authors:  Xiaoyu Kang; Bin Lu; Pan Xiao; Zhaolai Hua; Rui Shen; Jianping Wu; Juan Wu; Zhenfeng Wu; Chun Cheng; Junfeng Zhang
Journal:  J Healthc Eng       Date:  2022-04-18       Impact factor: 3.822

Review 5.  The role of microbiome in pancreatic cancer.

Authors:  Jenny Jing Li; Mojun Zhu; Purna C Kashyap; Nicholas Chia; Nguyen H Tran; Robert R McWilliams; Tanios S Bekaii-Saab; Wen Wee Ma
Journal:  Cancer Metastasis Rev       Date:  2021-08-28       Impact factor: 9.264

Review 6.  Connecting the Human Microbiome and Pancreatic Cancer.

Authors:  Rachel E Sexton; Md Hafiz Uddin; Sahar Bannoura; Husain Yar Khan; Yousef Mzannar; Yiwei Li; Amro Aboukameel; Mohammad Najeeb Al-Hallak; Bayan Al-Share; Amr Mohamed; Misako Nagasaka; Bassel El-Rayes; Asfar S Azmi
Journal:  Cancer Metastasis Rev       Date:  2022-04-02       Impact factor: 9.237

7.  Global research trends on the links between the gut microbiome and cancer: a visualization analysis.

Authors:  Sa'ed H Zyoud; Samah W Al-Jabi; Riad Amer; Muna Shakhshir; Moyad Shahwan; Ammar A Jairoun; Maha Akkawi; Adham Abu Taha
Journal:  J Transl Med       Date:  2022-02-11       Impact factor: 5.531

Review 8.  Armed to the Teeth-The Oral Mucosa Immunity System and Microbiota.

Authors:  Maja Ptasiewicz; Ewelina Grywalska; Paulina Mertowska; Izabela Korona-Głowniak; Agata Poniewierska-Baran; Paulina Niedźwiedzka-Rystwej; Renata Chałas
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

Review 9.  Oral Bacterial Microbiota in Digestive Cancer Patients: A Systematic Review.

Authors:  Elisa Reitano; Nicola de'Angelis; Paschalis Gavriilidis; Federica Gaiani; Riccardo Memeo; Riccardo Inchingolo; Giorgio Bianchi; Gian Luigi de'Angelis; Maria Clotilde Carra
Journal:  Microorganisms       Date:  2021-12-14

Review 10.  Bacterial and Parasitic Pathogens as Risk Factors for Cancers in the Gastrointestinal Tract: A Review of Current Epidemiological Knowledge.

Authors:  Janneke W Duijster; Eelco Franz; Jacques Neefjes; Lapo Mughini-Gras
Journal:  Front Microbiol       Date:  2021-12-08       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.